We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Center for Beta Cell Therapy in Diabetes and ViaCyte announced a human stem cell-derived product candidate has been implanted in type 1 diabetes patients at a subtherapeutic dose.....